Fatal exacerbation of paraneoplastic systemic sclerosis after neoadjuvant chemotherapy in a breast cancer patient

Clinical Rheumatology

Volumn 23, Issue 3, 2004, Pages 269-271

  Kochhar, Ruby ^a   Umbreit, Jay N ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Accelerated systemic sclerosis; Paraneoplastic; Pericarditis

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE;

ADULT; AFRICAN AMERICAN; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CARDIOPULMONARY ARREST; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE EXACERBATION; DRUG FATALITY; FEMALE; HEART TAMPONADE; HUMAN; KIDNEY FAILURE; PARANEOPLASTIC SYNDROME; PERICARDITIS; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIAC TAMPONADE; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FATAL OUTCOME; FEMALE; HUMANS; NEOADJUVANT THERAPY; PARANEOPLASTIC SYNDROMES; PERICARDITIS; SCLERODERMA, SYSTEMIC;

EID: 3042534624     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-004-0875-x     Document Type: Article

References (19)

1. Postlethwaite AE (1990) Early immune events in scleroderma. Rheum Dis Clin North Am 16:125-139
2. White B (1995) Immunologic aspects of scleroderma. Curr Opin Rheumatol 7:541-545
3. Whiteside TL, Kumagai Y, Roumm AD, Almendinger R, Rodnan GP (1983) Suppressor cell function and T lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis. Arthritis Rheum 26:841-847
4. Gustafsson R, Totterman TH, Klareskog L, Hallgren R (1990) Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis. Ann Rheum Dis 49: 40-45
5. Kahaleh MB (1991) Soluble immunologic products in scleroderma sera. Clin Immunol Immunopathol 58:139-144
6. Duncan SC, Winkelmann RK (1979) Cancer and Scleroderma. Arch Dermatol 115:950-955
7. Thomas E, Brewster DH, Black RJ, MacFarlane GJ (2000) Risk of malignancy among patients with rhematic conditions. Int J Cancer 88:497-502
8. Lee P, Alderdice C, Wilkinson S, Keystone EC, Urowitz MB, Gladman DD (1985) Malignancy in systemic sclerosis. J Rheumatol 12:1136-1138
9. Hill CL, Nguyen AM, Roder D, Roberts-Thomson (2003) Risk of cancer in patients with scleroderm: a population based cohort study. Ann Rheum Dis 62:728-731
10. Pearson JE, Silman AJ (2003) Risk of cancer in patients with scleroderma. Ann Rheum Dis 62:697-699
11. Querfeld C, Collbeg S, Huerkamp C, Eckes B, Krieg T (2000) Pseudoscleroderma associated with lung cancer: correlation of collagen type I and connective tissue growth factor gene expression. Br J Dermatol 142:1228-1233
12. Bielefeld P (1991) Systemic scleroderma and malignant disease. A review of the literature. Rev Med Interne 12:350-354
13. Berd D, Mastrangelo MJ (1987) Effect of low dose cyclo-phosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res 47:3317-3321
14. Bast RC Jr, Reinherz EL, Maver C, Lavin P, Schlossman SF (1983) Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. Clin Immunol Immunopathol 28:101-114
15. Booton R, Jeffery R, Prabhu PN (1999) Systemic sclerosis and scleroderma renal crisis in association with carcinoma of the breast. Am J Kidney Dis 34:937-941
16. Dewani MS, Qadri SR, Lone MA, Qureshi KA (2000) Progressive systemic sclerosis (scleroderma), carcinoma breast and valvular heart disease: an unusual combination. J Postgrad Med 46:181-183
17. Puett DW, Fuchs HA (1994) Rapid exacerbation of scleroderma in a patient treated with interleukin-2 and lymphokine-activated killer cells for renal cell carcinoma. J Rheumatol 21:752
18. Abdul Hamied TA, Parker D, Turk JL (1987) Effects of adriamycin, 4-hydroperoxycyclophosphamide and ASTA Z 7557 (INN mafosfamide) on the release of IL-2 and IL-1 in vitro. Int JImmunopharmacol 9:355-361
19. Goronzy JJ, Weyand CM (1990) Long-term immunomodulatory effects of T lymphocyte depletion in patients with systemic sclerosis. Arthritis Rheum 33:511-519